Clinical Trial Update: SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update comparing SCT-I10A plus SCT510 to sorafenib as first-line therapy for advanced hepatocellular carcinoma (PHASE 2/3).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• SCT-I10A
• SCT510
• Sorafenib (Sorafenib)

Snippet

Sponsor: Sinocelltech Ltd. | Conditions: Hepatocellular Carcinoma | Phase 2, Phase 3 | Status: UNKNOWN